Pathogenic variants in the X-linked gene ZC4H2, which encodes a zinc-finger protein, cause an infrequently described syndromic form of arthrogryposis multiplex congenita (AMC) with central and peripheral nervous system involvement. We present genetic and detailed phenotypic information on 23 newly identified families and simplex cases that include 19 affected females from 18 families and 14 affected males from nine families. Of note, the 15 females with deleterious de novo ZC4H2 variants presented with phenotypes ranging from mild to severe, and their clinical features overlapped with those seen in affected males. By contrast, of the nine carrier females with inherited ZC4H2 missense variants that were deleterious in affected male relatives, four were symptomatic. We also compared clinical phenotypes with previously published cases of both sexes and provide an overview on 48 males and 57 females from 42 families. The spectrum of ZC4H2 defects comprises novel and recurrent mostly inherited missense variants in affected males, and de novo splicing, frameshift, nonsense, and partial ZC4H2 deletions in affected females. Pathogenicity of two newly identified missense variants was further supported by studies in zebrafish. We propose ZC4H2 as a good candidate for early genetic testing of males and females with a clinical suspicion of fetal hypo-/akinesia and/ or (neurogenic) AMC.
| INTRODUCTION
Arthrogryposis multiplex congenita (AMC) has a prevalence of one case per 3,000-5,000 newborns. It is defined as multiple joint contractures that involve at least two different body areas before birth. AMC is a descriptive term and present in over 400 specific conditions (Hall, 1984 (Hall, , 2014 . One known causal factor is decreased fetal movement in utero (fetal hypo-/akinesia; Hall, 2009 ). AMC can result from a single gene defect or a chromosomal abnormality and can be part of various syndromes. In these cases, autosomal dominant, autosomal recessive, and X-linked inheritance are possible (Hall, 2014) . There are currently over 800 genes connected with either arthrogryposis or other types of early contractures with over 150 forms due to deleterious defects of X-linked genes (Hunter et al., 2015) .
One form of X-linked arthrogryposis was first described in 1985 in six men from three generations of one family and referred to as Wieacker-Wolff syndrome (WRWF; MIM# 314580; Wieacker, Wolff, Wienker, & Sauer, 1985) . All six affected had congenital contractures of the feet, slowly progressive predominantly distal muscle atrophy, visual dyspraxia, facial weakness, and intellectual disability (ID). In 2013, this family was reported to carry a pathogenic missense variant of the X-linked gene ZC4H2 (MIM # 300897) along with three additional unrelated families who carried ZC4H2 missense variants in males and females, an unrelated male with a de novo chromosomal inversion that truncated ZC4H2, and two unrelated females harboring heterozygous de novo ZC4H2 deletions (Hirata et al., 2013) . In zebrafish, zc4h2 knockdown caused abnormal swimming and impaired alpha-motor neuron development, which could not be rescued by mutant proteins containing the pathogenic substitutions (Hirata et al., 2013) .
In 2015, May et al. identified ZC4H2 variants in four additional families, including a large family with syndromic X-linked ID (XLID; MRXS4), previously described as having Miles-Carpenter syndrome (MCS; Miles & Carpenter, 1991) and characterized by XLID, exotropia, distal muscle wasting, microcephaly, congenital contractures, and low digital arches (May et al., 2015) . Most recently, three simplex females with heterozygous de novo deleterious ZC4H2 were reported, including an early truncating nonsense variant and two microdeletions (Godfrey, Dowlatshahi, Martin, & Rothkopf, 2018; Okubo et al., 2018; Zanzottera et al., 2017) . As a result of these findings, these various allelic syndromes are now referred to as ZC4H2-associated rare disorders (ZARD).
We here report 23 additional ZARD families and simplex cases with inherited or de novo pathogenic ZC4H2 variants plus three cases with publicly available information in DECIPHER (https://decipher.sanger.ac.uk/). We compared the genetic and clinical results with previously published families, thereby extending the molecular and clinical spectrum of ZARD throughout life, and discuss the broad clinical spectrum and its clinical variability in both males and females. Furthermore, we report a late adult-onset mild form of slowly progressive spastic paraplegia in ZC4H2 carrier females of one previously published family (Hennekam, Barth, Van Lookeren Campagne, De Visser, & Dingemans, 1991; Hirata et al., 2013) . We emphasize that the ZARD phenotype in females with a pathogenic de novo ZC4H2 variant can be highly variable.
| MATERIALS AND METHODS

| Editorial policies and ethical considerations
The study was carried out in accordance with the Declaration of Helsinki and the protocol approved by the local ethical committees for clinical genetic investigations. Written informed consent was obtained for molecular genetic analysis, publication of clinical, radiological data, and photographs from all participants or their legal guardians.
| Genetic studies
DNAs were extracted from peripheral blood, skin fibroblasts, buccal cells, or umbilical cord using standard procedures. Families 1, 14, 16, and 18 (DECIPHER Patient IDs: 263304, 263305, 260529, 276496, and 296515) were recruited to the Deciphering Developmental Disorders (DDD) study. DNA samples were analyzed by the Wellcome Sanger Institute using array-CGH and whole exome sequencing (WES; Wright et al., 2015) . For families 2, 8, 13, 15, 19 , and 24 trio WES was performed as described in more detail in Supporting Information Materials and Methods, and for families 3 and 5 essentially as reported previously (Neveling et al., 2013) . For families 4 and 6 all ZC4H2 coding exons were amplified by polymerase chain reaction (PCR) and Sanger sequenced with gene-specific primer pairs previously published (Hirata et al., 2013) . Also for family 6, all TYR and OCA2 coding exons were amplified by PCR and Sanger sequenced. For family 7, see, Hennekam et al. (1991) and Hirata et al. (2013) . For family 9 WES was performed for the index proband ( Figure 1 , V:1), his unaffected parents (III:1 and III:2) and two of his affected male relatives (III:5 and IV:2). For family 17 WES was performed for the index proband ( Figure 1 , II:1) in a research context. For families 3 (umbilical DNA of II:3), 10, 11, 12, 20, and 23 array-CGH was carried out, and for family 12 the breakpoints of the chromosomal deletion were fine-mapped by serial PCR and bidirectional Sanger sequencing (for further details see Supporting Information and Figure S1 ). For family 21, trio whole genome sequencing (WGS) was performed on peripheral blood DNA from the proband and both parents through the 100,000 Genomes Project (The 100,000 (Arachchi et al., 2018; Philippakis et al., 2015; Sobreira et al., 2017) . For family 24 trio WES was performed at Fulgent Genetics, US.
The ZC4H2 variants identified by WES and WGS were subsequently confirmed in the patients using Sanger sequencing. Segregation analysis of the variants was performed using standard Sanger sequencing with gene-specific primers and for family 9 using restriction digestion of the specific PCR product (see Supporting Information for more details).
The novel ZC4H2 variants identified through this study have been submitted to the LOVD database (https://databases.lovd.nl/shared/ genes/ZC4H2).
| X-inactivation studies
For X-inactivation studies, DNA extracted from blood lymphocytes or skin fibroblasts was analyzed for the methylation sensitive site of FMR1 exon 1 (Carrel & Willard, 1996) , the CAG-repeat of the Androgen Receptor (AR) gene (Allen, Zoghbi, Moseley, Rosenblatt, & Belmont, 1992) , or of ZMYM3.
| In silico analysis
The pathogenicity of missense variants was assessed using in silico tools including Combined Annotation Dependent Depletion (CADD, http://cadd.gs.washington.edu/) score (Kircher et al., FRINTS ET AL. | 3 F I G U R E 1 Pedigrees of the families with pathogenic ZC4H2 variants discovered by candidate gene approach, whole exome/genome sequencing and array-CGH. Families 1, [4] [5] [6] 8, 9, 15, 18, 19, and 24 with likely pathogenic ZC4H2 missense variants, families 2, 3, 13, 14, 16, 17, 21, and 22 with splicing, frameshift, and stop codon variants and families 10-12, 20, and 23 with a microdeletion removing the 5′ part of ZC4H2, Fam, family; *, variant present; wt, wild-type. For family 7 see Figure S2 2014) and Provean (http://provean.jcvi.org/index.php; Choi & Chan, 2015) .
| Extraction of variants and clinical phenotypes from the literature and the DECIPHER database
We established a list of all published ZC4H2 variants reported in the literature as of January 2019 and three cases from DECIPHER, and included available clinical information in our analysis.
| Knockdown and rescue experiments in zebrafish
Zebrafish were bred and maintained according to approved guidelines prescribed by the Committee on Use and Care of Animals at Aoyama Gakuin University (Japan). Zebrafish zc4h2 (GenBank NM_199642) cloned into pCR4-TOPO vector (Invitrogen) was used for cRNA synthesis as previously described (Hirata et al., 2013) . Antisense morpholino oligonucleotides (MO) designed against the exon 2-intron 2 splice donor site (MO2) of zebrafish zc4h2 were used for knocking down zc4h2.
Zebrafish embryos were injected with 5 ng of MOs at 1-2 cell stages and studied as published before (Hirata et al., 2013) . For rescue experiments, the missense variants were introduced into the wild-type mouse Zc4h2 (RefSeq NM_001003916.2) pCS2+ expression construct by site-directed mutagenesis (primer sequences are provided in Table S1 ). Capped RNA was synthesized using mMESSAGE mMACHINE SP6 kit (Life Technologies) according to the manufacturer's protocol. Capped RNA (100 pg) was coinjected with MO2 (4 ng) into zebrafish embryos at 1-2 cell stages.
At 2 days postfertilization, normal zebrafish embryos swim away rapidly (> 2 cm/s) upon tactile stimulation. The number of embryos that exhibited slow swimming (< 2 cm/s) following touch was counted.
| ZC4H2 reference sequence
All ZC4H2 variants reported are based on GRCh37/hg19 and transcript isoform 1 (RefSeq NM_018684.3) with nucleotide (cDNA) numbering using +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.
| RESULTS
| Clinical features in the new patient cohort and in previously published families
We report on 23 novel families and simplex cases with likely deleterious ZC4H2 variants and on one previously published family, family 7 of this study (Hennekam et al., 1991; Hirata et al., 2013) . The pedigrees of the novel families are shown in Figure 1 (Fam1-6 and Fam8-24) and of family 7 in Figure S2 . Detailed clinical descriptions are presented in Supporting Information Results. In the clinical evaluation, we also included publicly accessible information of three females reported to DECIPHER and all families and simplex cases published to date (Godfrey et al., 2018; Hirata et al., 2013; Kondo et al., 2018; May et al., 2015; Okubo et al., 2018; Zanzottera et al., 2017) . A compilation of the main (≥ 30%) clinical features of affected males and females from these 42 families is given in Table 1 and of the additional less common clinical features (< 30%) in Table S2 .
Percentages are related to the total number of probands who were clinically evaluated for a given feature (positive informative). In total, informative clinical data were collected for 87 out of 105 (83%) probands, including 44 out of 48 (92%) males and 43 out of 57 (75%) females using the Human Phenotype Ontology (https://hpo.jax.org/ app/) scoring list. Their ages ranged from 23 weeks of gestation to > 70 years at the time of clinical genetic investigation. Families were recruited worldwide and were of Caucasian and Asian ethnicity.
Prenatal presentation of five fetuses with ZARD (two males and three females), included club foot/feet, rocker bottom feet, fetal hypo/akinesia (mostly at the end of the second or third trimester of pregnancy, > 18-26 weeks of gestation), contractures, AMC, nuchal and/or frontal head edema and (nearly) normal growth parameters (See Videos S1-3 and Figure S3 ). One affected male fetus presented with hypogenitalism (cryptorchidism and micropenis). In marked contrast, the 25 females with a de novo pathogenic variant (from neonatal age till adulthood) of ZC4H2 including Xq11.2 microdeletions showed high variation in clinical presentation and ranged from mildly to severely affected (Table 1; Table S2 ).
Overall, common clinical features in child-and adulthood in both males and females (30% or more positive informative in probands) included postnatal growth retardation, generalized hypotonia, motor delay, inability to walk, spasticity, hyperreflexia, urinary incontinence, dysarthria-deficit in expressive language, poor or absent speech, ID, drooling, dysphagia, chewing difficulties including oral motor dysfunction, feeding difficulties, facial weakness-palsy, high forehead, high anterior hairline, ocular motor apraxia, strabismus, anteverted nares, microretrognathia, AMC, limited shoulder movement, elbow, wrist contractures, metacarpophalangeal joint contractures, camptodactyly, radial deviation of any finger, knee flexion contractures, n/a n/a n/a n/a n/a n/a n/a n/a n/a 7 12 58 Cryptorchidism 28 9 17 53 n/a n/a n/a n/a n/a n/a n/a n/a n/a Figure S5 ). Of note, neonatal respiratory distress, recurrent aspiration pneumonia, and (obstructive sleep) apnea can be a particular concern with apnea more frequently reported in males (11/16) than in affected females with a de novo variant (3/11). In addition reported clinical features included narrow chest, narrow shoulders-thorax (more frequently reported in females with a de novo variant (11/15) than in affected males (18/36); Figure S5 ), umbilical hernia ( Figure S3A Figure S4 ), arrhythmia, sick sinus syndrome, hypoglycemia, and aggressive behavior were so far only reported in males (Table 1 and (stress) incontinence (16/28) were also mentioned. MRI brain and spine images showed variable and global brain atrophy (11/31; examples are given in Figure S6 Table S2 . Abbreviations: %, percentage; HPO, human phenotype ontology; nr, number; n/a, not applicable; w, weeks; y, years.
*positive informative/total informative.
(4/27), corpus callosum abnormality (7/26), abnormal cortical gyration (5/24), ventriculomegaly (8/20), polymicrogyria, anterior to posterior gradient (1/8 males), tethered cord (3/19), and hydromyelia (2/10 males). Abnormal peripheral nerve conduction was present in one affected (1/7 males). Behavioral phenotypes included emotional lability (5/14) and aggressive behavior (3/5 males; Table S2 ).
Cardiovascular associated clinical features, for example, arrhythmia (5/13), bradycardia (5/8), (congenital) sick sinus syndrome (5/13), and right ventricular hypertrophy (4/12) were so far reported in affected males only (Table S2 ).
| ZC4H2 genetic characteristics in the new cohort and global mutational spectrum
Most of the novel families were investigated by WES, WGS and/or array-CGH. For two affected index males (family 4, II:2 and family 6, III:1) it was assumed that the phenotype could be caused by a pathogenic ZC4H2 variant and therefore all coding exons were screened by Sanger sequencing.
A total of eight males from six families (families 1, 3, 4, 5, 9, and 19) inherited the variant from a healthy carrier mother, while three males from three families (families 5, 6, and 9) inherited the variant from a mildly affected mother (Figure 1 ). For one affected male (family 9, II:5) the phenotype of his mother is unknown. In the moderately affected male A total of 23 variants were identified (Figure 2a,b,c) . Thirteen of the 23 were de novo loss-of-function variants (nonsense, splice-site, frameshift, and CNVs) present in affected females and 10 were missense variants identified in affected males which, except for the two de novo variants in affected males (families 18 and 24), were inherited from their mildly affected or asymptomatic carrier mothers.
Twenty of the 23 variants were novel including single nucleotide variants (SNVs) and five de novo microdeletions in females. The microdeletions removed the first exon of ZC4H2 but did not affect any adjacent genes. Two missense variants were defined as recurrent. Families 4 and 24 of this study carry a previously reported p.(Arg198Gln) change in an unrelated family (Hirata et al., 2013) .
Family 18 of this study has a de novo p.(Arg213Trp) variant previously reported in three unrelated families (Hirata et al., 2013; May et al., 2015) . Also, in two families in this study (families 5 and 6) the same amino acid (Ala200) was altered. Finally, the proline residue 201 mutated to serine in a published family (Hirata et al., 2013 ) was mutated to histidine in family 19 of this study.
None of the variants identified in this study were reported in publicly and supporting our suggestion that they are deleterious to protein function. All missense variants altered highly conserved amino acids (fully conserved from human to zebrafish; Figure 2d and Figure S8 ). Also, in silico predictions using CADD revealed high scores (> 22) and using
Provean all variants were predicted as deleterious, except for the p.(Lys217Arg) change, which perfectly cosegregated with the phenotype in a large family (Fam9). At the gene level, ZC4H2 is highly constrained with a pLI score of 0.91 and zero known LOF mutations in gnomAD (Lek et al., 2016) .
Combined with our results of this study, there are currently 31 unique ZC4H2 variants known in affected males and females, including one de novo X-inversion interrupting ZC4H2 in a male plus 10 de novo Xq11.2 microdeletions in females (Figure 2a ). An overview of all variants is provided in Table S3 . Thus far, SNVs leading to missense changes cluster in the last exon of ZC4H2, which encodes the zinc-finger domain and the most C-terminal part of the protein.
The X-inactivation pattern in blood or skin fibroblasts in affected females varied from random to skewed and was not useful to predict the phenotype (Figure 1 and Supporting Information Results), for example, one severely affected female fetus showed an Xi ratio of 61:39 in skin fibroblasts (Figure 1, Fam3, II:3) . Other mild to severely affected females showed Xi ratios varying between 100:0 and 80:20 ( Figure 1 ) in blood lymphocytes. Previous asymptomatic carrier females reported in the literature showed also a ratio of > 95:5 (e.g., Hirata et al., 2013) .
| Zebrafish studies
We investigated the potential effects of the p.(Ala200Val) and p.(His70Gln) missense variants which we identified early on in zebrafish morphants similar to our previous studies (Hirata et al., 2013 
| DISCUSSION
This study reports on the genetic and clinical findings of 23 novel families and simplex cases with deleterious inherited or de novo ZC4H2 variants identified in males and females, including de novo FRINTS ET AL.
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F I G U R E 2 Overview of genetic results in ZARD affected males and females. An overview of newly identified likely pathogenic variants of ZC4H2 described here and previously reported in the literature. (a) Schematic view of the X chromosome with the location of ZC4H2 and the five known RNA isoforms. Horizontal bars indicate the de novo complete ZC4H2 deletions in affected females published previously (Hirata et al., 2013; Okubo et al., 2018; Zanzottera et al., 2017) , DECIPHER case 323746 and the newly identified de novo ZC4H2 microdeletions removing part of ZC4H2 identified in this study (families 10-12, 20, and 23). All deletions removed ZC4H2 exon 1 but no other known gene. (b) The structure of human ZC4H2 (Isoform 1; NM_018684.3) with nontranslated sequences gray-striped, exons encoding the coiled-coil domain in gray, and exons encoding the zinc-finger domain in white. Newly identified pathogenic ZC4H2 variants identified in this study are depicted above the gene with de novo variants in affected females underlined. Likely pathogenic variants from the literature are depicted below the gene and protein. (c) Schematic representation of ZC4H2 protein isoform 1 (NP_061154.1) with its functional domains (CC domain: Coiled coil domain; ZNF: zinc-finger domain). ZC4H2 variants newly identified in this study are depicted above the protein with de novo variants in females underlined and variants from the literature are depicted below the protein. hypotonia, spasticity (as seen in SPG16 [Steinmuller et al., 1997] ), mild facial dysmorphism, for example, high forehead with high frontal hairline, ocular dyspraxia, relative short stature, and (relative) microcephaly. The differential diagnosis is still challenging and earlier reported XLID families could benefit from WES including ZC4H2 analysis (Table S4) .
In contrast to the mostly inherited missense variants in affected males, the spectrum of de novo pathogenic ZC4H2 variants identified in affected females includes missense, early stop, frameshift and splicing variants, as well as Xq11.2 microdeletions which removed ZC4H2 completely or exon 1 of all transcript isoforms. Thus, from the current data it seems that pathogenic variants predicted to lead to a complete loss of ZC4H2 protein function are very rare in males, while they usually occur de novo in females. Of note, none of the pathogenic variants identified in males were found de novo in female simplex cases. The de novo variants in the affected females are predicted to be loss-of function alleles, suggesting ZC4H2 insufficiency as the most likely pathological mechanism leading to an Xlinked dominant phenotype.
Our detailed clinical characterization ( (Hennekam et al., 1991) indicated very mild progressive muscle weakness in two former asymptomatic carrier females and marked progression including loss of the ability to walk and distal muscle wasting in one carrier female ( Figure S2 , III:5, III:7, and III:14) . She also had episodic periods of pain of unknown origin. All three females had inability to smell and urine stress incontinence. has previously been reported in a large German family (Hirata et al., 2013) and there are phenotypic overlaps with affected males being severely affected. Secondly, the de novo p.(Arg213Trp) substitution identified in a moderately affected male (family 18) has previously been reported in three large families (Hirata et al., 2013; May et al., 2015) . ZC4H2 is known as a gene which is subject to X-inactivation.
Current results suggest that, in heterozygous carrier females, Xinactivation status in blood and skin fibroblasts does not predict the clinical outcome. This is very much in line with results obtained for other X-linked disease genes and also with recent findings suggesting that skewed X-inactivation is common in the general female population (Shvetsova et al., 2018) . Still, the variable clinical manifestations of heterozygous carrier females with a de novo variant ranging from very mildly to severely affected may be partially explained by the X-inactivation status within specific affected cells and tissues. However, other genetic, environmental, or stochastic factors may also be involved and could have an impact on phenotypic variability and severity of ZARD.
Similar to patients with other types of AMC who develop joint contractures during pregnancy, abnormal fetal movement due to ZARD can be identified using real time ultrasound prenatally, as we report here for affected fetuses from several families (for family 3 see Videos S1-3). An early diagnosis of AMC prenatally would allow parents and clinicians early decision making, for example, the possibility of in utero therapy (increasing movement in utero), or early delivery at a time when lungs are mature but the contractures may not yet be so severe (Hall, Agranovich, Ponten, & van Bosse, 2015) . However, AMC and fetal hypo-/akinesia can occur late in pregnancy, after routine prenatal ultrasound sonography has taken place between 18 and 22 weeks of gestation, thus the diagnosis of AMC and/or fetal hypo-/akinesia can be easily missed. Moreover, reduced fetal hand, finger and feet movements are not examined routinely by ultrasound and occasionally club foot/feet is/are the only clinical feature which fetuses with a pathogenic ZC4H2 variant presented prenatally or neonatally.
In conclusion, ZC4H2 is one of the more commonly mutated XL-AMC and XLID genes. Up to now de novo pathogenic variants of ZC4H2 have been more frequently seen in affected females than in males with ZARD and displayed a broad clinical spectrum ranging from mildly to severely affected patients with neurogenic AMC with or without CNS and PNS involvement (see Supporting Information).
Our findings suggest including ZC4H2 analysis retrospectively in AMC male and female cohorts and prospectively in prenatal and/or neonatal genetic diagnostic tests in male and female fetuses presenting with fetal hypo-/akinesia and/or AMC, for example, (only) club foot/feet with or without hypogenitalism in males. Long-term prospective clinical studies assessing the development of the ZARD phenotypes and investigations determining the molecular and cellular mechanisms underlying the disorders are required.
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